The group’s principle activity is to develop first or best-in-class human antibody therapeutics. The group’s programs include KB001 for Pseudomonas aeruginosa infections, and KB002 an anti-inflammatory for rheumatoid arthritis. The group operates from United States.
Executive Information
Name
Title
Email
James Healy
Chmn.
N/A
David Pritchard
CEO, Pres.
N/A
Geoffrey Yarranton
Chief Scientific Officer, Exec. VP - Research, Development
